

William E Klunk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/244878/publications.pdf>

Version: 2024-02-01

230
papers

47,490
citations

9428

76
h-index

2289

206
g-index

248
all docs

248
docs citations

248
times ranked

33116
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Biomarker clustering in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2023, 19, 274-284. | 0.4 | 2 |
| 2 | Direct Comparison of the Tau PET Tracers ¹⁸ F-Flortaucipir and ¹⁸ F-MK-6240 in Human Subjects. <i>Journal of Nuclear Medicine</i> , 2022, 63, 108-116. | 2.8 | 39 |
| 3 | Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228. | 4.5 | 97 |
| 4 | White matter microstructure associations to amyloid burden in adults with Down syndrome. <i>NeuroImage: Clinical</i> , 2022, 33, 102908. | 1.4 | 1 |
| 5 | Variant-dependent heterogeneity in amyloid β^2 burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study. <i>Lancet Neurology</i> , The, 2022, 21, 140-152. | 4.9 | 34 |
| 6 | Cortical atrophy and amyloid and tau deposition in Down syndrome: A longitudinal study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12288. | 1.2 | 2 |
| 7 | Support vector machine learning and diffusion-derived structural networks predict amyloid quantity and cognition in adults with Down's syndrome. <i>Neurobiology of Aging</i> , 2022, 115, 112-121. | 1.5 | 2 |
| 8 | Brain health correlates of mobility-related confidence. <i>Experimental Gerontology</i> , 2022, 163, 111776. | 1.2 | 1 |
| 9 | ¹¹ C-PiB PET can underestimate brain amyloid- β^2 burden when cotton wool plaques are numerous. <i>Brain</i> , 2022, 145, 2161-2176. | 3.7 | 8 |
| 10 | Joint α -label fusion brain atlases for dementia research in Down syndrome. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, . | 1.2 | 1 |
| 11 | Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers. <i>JAMA Neurology</i> , 2022, 79, 797. | 4.5 | 17 |
| 12 | Alzheimer's disease pathology in a community-based sample of older adults without dementia: The MYHAT neuroimaging study. <i>Brain Imaging and Behavior</i> , 2021, 15, 1355-1363. | 1.1 | 7 |
| 13 | Development of a PET radioligand selective for cerebral amyloid angiopathy. <i>Nuclear Medicine and Biology</i> , 2021, 92, 85-96. | 0.3 | 6 |
| 14 | Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging. <i>Molecular Psychiatry</i> , 2021, 26, 309-321. | 4.1 | 47 |
| 15 | Radiosynthesis, <i>In Vitro</i> and <i>In Vivo</i> Evaluation of [¹⁸ F]CBD-2115 as a First-in-Class Radiotracer for Imaging 4R-Tauopathies. <i>ACS Chemical Neuroscience</i> , 2021, 12, 596-602. | 1.7 | 29 |
| 16 | Neurofibrillary tau depositions emerge with subthreshold cerebral beta-amyloidosis in down syndrome. <i>NeuroImage: Clinical</i> , 2021, 31, 102740. | 1.4 | 9 |
| 17 | PET measurement of longitudinal amyloid load identifies the earliest stages of amyloid-beta accumulation during Alzheimer's disease progression in Down syndrome. <i>NeuroImage</i> , 2021, 228, 117728. | 2.1 | 15 |
| 18 | Robust White Matter Hyperintensity Segmentation On Unseen Domain. , 2021, 2021, 1047-1051. | | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Multi-Domain Learning By Meta-Learning: Taking Optimal Steps In Multi-Domain Loss Landscapes By Inner-Loop Learning. , 2021, 2021, 650-654. | | 3 |
| 20 | An Effect of Education on Memory-Encoding Activation in Subjective Cognitive Decline. Journal of Alzheimer's Disease, 2021, 81, 1065-1078. | 1.2 | 5 |
| 21 | Characterization of point-spread function specification error on Geometric Transfer Matrix partial volume correction in [11C]PiB amyloid imaging. EJNMMI Physics, 2021, 8, 54. | 1.3 | 0 |
| 22 | Comparing amyloid- β plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease. Acta Neuropathologica, 2021, 142, 689-706. | 3.9 | 15 |
| 23 | Peripheral inflammatory biomarkers predict the deposition and progression of amyloid- β in cognitively unimpaired older adults. Brain, Behavior, and Immunity, 2021, 95, 178-189. | 2.0 | 22 |
| 24 | Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study. Lancet Neurology, The, 2021, 20, 615-626. | 4.9 | 26 |
| 25 | Comparing Pathological Risk Factors for Dementia between Cognitively Normal Japanese and Americans. Brain Sciences, 2021, 11, 1180. | 1.1 | 0 |
| 26 | Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET. Neurology, 2021, 97, e1823-e1834. | 1.5 | 35 |
| 27 | Physical activity and cognitive and imaging biomarkers of Alzheimer's disease in down syndrome. Neurobiology of Aging, 2021, 107, 118-127. | 1.5 | 17 |
| 28 | What Is T+? A Gordian Knot of Tracers, Thresholds, and Topographies. Journal of Nuclear Medicine, 2021, 62, 614-619. | 2.8 | 21 |
| 29 | A multi-scanner neuroimaging data harmonization using RAVEL and ComBat. NeuroImage, 2021, 245, 118703. | 2.1 | 31 |
| 30 | The effect of amyloid deposition on longitudinal resting-state functional connectivity in cognitively normal older adults. Alzheimer's Research and Therapy, 2020, 12, 7. | 3.0 | 14 |
| 31 | Improving brain age prediction models: incorporation of amyloid status in Alzheimer's disease. Neurobiology of Aging, 2020, 87, 44-48. | 1.5 | 38 |
| 32 | Cerebrospinal fluid biomarkers of Alzheimer's disease in a cohort of adults with Down syndrome. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12057. | 1.2 | 15 |
| 33 | Associations between NIH Toolbox Cognition Battery and <i>in vivo</i> brain amyloid and tau pathology in non-demented older adults. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12018. | 1.2 | 17 |
| 34 | Predicting resistance to amyloid-beta deposition and cognitive resilience in the oldest-old. Neurology, 2020, 95, e984-e994. | 1.5 | 14 |
| 35 | Hippocampal sclerosis, TDP β 43, and the duration of the symptoms of dementia of AD patients. Annals of Clinical and Translational Neurology, 2020, 7, 1546-1556. | 1.7 | 15 |
| 36 | Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid- β plaques in Alzheimer's disease. Acta Neuropathologica, 2020, 140, 463-476. | 3.9 | 34 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | White matter microstructure and episodic memory in adults with down syndrome: A Tract-Based Spatial Statistics (TBSS) Study. <i>Alzheimer's and Dementia</i> , 2020, 16, e044673. | 0.4 | 1 |
| 38 | Evaluation of amyloid and tau PET quantitation methods using a 3D-printed anatomically accurate brain phantom. <i>Alzheimer's and Dementia</i> , 2020, 16, e045455. | 0.4 | 0 |
| 39 | Amyloid accumulation in Down syndrome measured with amyloid load. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12020. | 1.2 | 19 |
| 40 | The roles of study setting, response bias, and personality in subjective memory complaints of cognitively normal older adults. <i>International Psychogeriatrics</i> , 2020, 33, 1-12. | 0.6 | 3 |
| 41 | A randomized controlled trial of amyloid positron emission tomography results disclosure in mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2020, 16, 1330-1337. | 0.4 | 19 |
| 42 | Influence of apolipoprotein-E genotype on brain amyloid load and longitudinal trajectories. <i>Neurobiology of Aging</i> , 2020, 94, 111-120. | 1.5 | 15 |
| 43 | Relationship of amyloid- β 42 in blood and brain amyloid: Ginkgo Evaluation of Memory Study. <i>Brain Communications</i> , 2020, 2, fcz038. | 1.5 | 10 |
| 44 | Association of sleep with cognition and beta amyloid accumulation in adults with Down syndrome. <i>Neurobiology of Aging</i> , 2020, 93, 44-51. | 1.5 | 24 |
| 45 | Metabolic correlates of prevalent mild cognitive impairment and Alzheimer's disease in adults with Down syndrome. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12028. | 1.2 | 12 |
| 46 | Cognitive indicators of transition to preclinical and prodromal stages of Alzheimer's disease in Down syndrome. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12096. | 1.2 | 20 |
| 47 | Patterns of glucose hypometabolism in Down syndrome resemble sporadic Alzheimer's disease except for the putamen. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12138. | 1.2 | 7 |
| 48 | Statistical Methods for Processing Neuroimaging Data from Two Different Sites with a Down Syndrome Population Application. <i>Communications in Computer and Information Science</i> , 2020, , 367-379. | 0.4 | 1 |
| 49 | Imaging neurodegeneration in Down syndrome: brain templates for amyloid burden and tissue segmentation. <i>Brain Imaging and Behavior</i> , 2019, 13, 345-353. | 1.1 | 21 |
| 50 | Neuropathological correlates of amyloid PET imaging in Down syndrome. <i>Developmental Neurobiology</i> , 2019, 79, 750-766. | 1.5 | 34 |
| 51 | Research Use of Ecological Momentary Assessment for Adverse Event Monitoring Following Amyloid- β Results Disclosure. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 1071-1079. | 1.2 | 7 |
| 52 | Investigating Gains in Neurocognition in an Intervention Trial of Exercise (IGNITE): Protocol. <i>Contemporary Clinical Trials</i> , 2019, 85, 105832. | 0.8 | 26 |
| 53 | Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 180-190. | 1.2 | 84 |
| 54 | Association Between Amyloid- β , Small-vessel Disease, and Neurodegeneration Biomarker Positivity, and Progression to Mild Cognitive Impairment in Cognitively Normal Individuals. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2019, 74, 1753-1760. | 1.7 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Leisure Activity, Brain β -Amyloid, and Episodic Memory in Adults with Down Syndrome. <i>Developmental Neurobiology</i> , 2019, 79, 738-749. | 1.5 | 14 |
| 56 | P4631: ALZHEIMER'S DISEASE PATHOLOGY IN A COMMUNITY-BASED SAMPLE OF OLDER ADULTS WITHOUT DEMENTIA: A POPULATION-NEUROSCIENCE APPROACH. <i>Alzheimer's and Dementia</i> , 2019, 15, P1569. | 0.4 | 0 |
| 57 | Longitudinal trajectories of amyloid deposition, cortical thickness, and tau in Down syndrome: A deep-phenotyping case report. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 654-658. | 1.2 | 13 |
| 58 | IC603: SPATIAL ASSOCIATIONS OF β WITH TAU DEPOSITION IN DOWN SYNDROME. <i>Alzheimer's and Dementia</i> , 2019, 15, P11. | 0.4 | 0 |
| 59 | IC604: SLEEP, COGNITION, AND β AMYLOID IN ADULTS WITH DOWN SYNDROME. <i>Alzheimer's and Dementia</i> , 2019, 15, P12. | 0.4 | 1 |
| 60 | IC602: ASSOCIATIONS BETWEEN β AND TAU IN ADULTS WITH DOWN SYNDROME. <i>Alzheimer's and Dementia</i> , 2019, 15, P11. | 0.4 | 0 |
| 61 | IC601: ASSESSMENT OF LONGITUDINAL AMYLOID LOAD CHANGE IN DOWN SYNDROME. <i>Alzheimer's and Dementia</i> , 2019, 15, P10. | 0.4 | 0 |
| 62 | Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease. <i>Molecular and Cellular Neurosciences</i> , 2019, 97, 3-17. | 1.0 | 82 |
| 63 | Multisite study of the relationships between <i>antemortem</i> [¹¹ C]PIB-PET Centiloid values and <i>postmortem</i> measures of Alzheimer's disease neuropathology. <i>Alzheimer's and Dementia</i> , 2019, 15, 205-216. | 0.4 | 155 |
| 64 | Comparison of longitudinal β in nondemented elderly and Down syndrome. <i>Neurobiology of Aging</i> , 2019, 73, 171-176. | 1.5 | 13 |
| 65 | Distinct cytokine profiles in human brains resilient to Alzheimer's pathology. <i>Neurobiology of Disease</i> , 2019, 121, 327-337. | 2.1 | 79 |
| 66 | Amyloid deposition is associated with different patterns of hippocampal connectivity in men versus women. <i>Neurobiology of Aging</i> , 2019, 76, 141-150. | 1.5 | 6 |
| 67 | Amyloid deposition and brain structure as long-term predictors of MCI, dementia, and mortality. <i>Neurology</i> , 2018, 90, e1920-e1928. | 1.5 | 36 |
| 68 | Prevalence of the apolipoprotein E ϵ 4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 913-924. | 0.4 | 58 |
| 69 | Molecular imaging: What is right and what is an illusion?. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 217-220. | 1.2 | 11 |
| 70 | Association of Cerebral Amyloid- β Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018, 75, 84. | 6.0 | 133 |
| 71 | Amyloid β Deposition and Suspected Non-Alzheimer Pathophysiology and Cognitive Decline Patterns for 12 Years in Oldest Old Participants Without Dementia. <i>JAMA Neurology</i> , 2018, 75, 88. | 4.5 | 33 |
| 72 | P3440: COMPARING THE CENTILOID SCALE FOR PITTSBURGH COMPOUND B AND FLORBETAPIR IN LONGITUDINAL PET STUDIES OF SPORADIC AD. <i>Alzheimer's and Dementia</i> , 2018, 14, P1283. | 0.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | O2â€³â€³06: PREDICTING RESILIENCY AGAINST AMYLOIDâ€³BETA DEPOSITION, COGNITIVE IMPAIRMENT, AND THEIR COMBINATION IN THE OLDESTâ€³OLD. Alzheimer's and Dementia, 2018, 14, P619. | 0.4 | 0 |
| 74 | ICâ€³Pâ€³210: COMPARISON OF IN VIVO [Fâ€³18]AVâ€³1451 OFFâ€³TARGET RETENTION IN AFRICANâ€³AMERICANS AND CAUCASIANS. Alzheimer's and Dementia, 2018, 14, P173. | 0.4 | 0 |
| 75 | P1â€³421: COMPARISON OF STRIATAL LONGITUDINAL CHANGES IN AMYLOID DEPOSITION IN NONâ€³DEMENTED ELDERLY AND DOWN SYNDROME. Alzheimer's and Dementia, 2018, 14, P467. | 0.4 | 0 |
| 76 | ICâ€³Pâ€³009: COMPARING THE CENTILOID SCALE FOR PITTSBURGH COMPOUND B AND FLORBETAPIR IN LONGITUDINAL PET STUDIES OF SPORADIC AD. Alzheimer's and Dementia, 2018, 14, P19. | 0.4 | 0 |
| 77 | ICâ€³Pâ€³020: PREDICTING RESILIENCY AGAINST AMYLOIDâ€³BETA DEPOSITION, COGNITIVE IMPAIRMENT, AND THEIR COMBINATION IN THE OLDESTâ€³OLD. Alzheimer's and Dementia, 2018, 14, P25. | 0.4 | 0 |
| 78 | ICâ€³Pâ€³004: AMYLOID BURDEN AND CORTICAL ATROPHY IN NONâ€³DEMENTED DOWN SYNDROME. Alzheimer's and Dementia, 2018, 14, P16. | 0.4 | 0 |
| 79 | P1â€³437: PULSE WAVE VELOCITY IS ASSOCIATED WITH INCIDENT DEMENTIA AND AMYLOID DEPOSITION IN THE BRAINS OF ELDERLY ADULTS. Alzheimer's and Dementia, 2018, 14, P477. | 0.4 | 0 |
| 80 | P1â€³429: COMPARISON OF IN VIVO [Fâ€³18]AVâ€³1451 OFFâ€³TARGET RETENTION IN AFRICAN AMERICANS AND CAUCASIANS. Alzheimer's and Dementia, 2018, 14, P473. | 0.4 | 0 |
| 81 | P1â€³445: AMYLOID BURDEN AND CORTICAL ATROPHY IN NONâ€³DEMENTED DOWN SYNDROME. Alzheimer's and Dementia, 2018, 14, P484. | 0.4 | 0 |
| 82 | FTS3â€³01â€³01: HISTORY OF AMYLOID PET. Alzheimer's and Dementia, 2018, 14, P1004. | 0.4 | 0 |
| 83 | Synergism of antihypertensives and cholinesterase inhibitors in Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 542-555. | 1.8 | 10 |
| 84 | The use of Centiloids for applying [¹¹ C]PiB classification cutoffs across regionalâ€³ofâ€³interest delineation methods. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 332-339. | 1.2 | 22 |
| 85 | Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies. NeuroImage: Clinical, 2018, 19, 406-416. | 1.4 | 76 |
| 86 | Impact of partial volume correction on the regional correspondence between in vivo [C-11]PiB PET and postmortem measures of A β load. NeuroImage: Clinical, 2018, 19, 182-189. | 1.4 | 13 |
| 87 | Sleep moderates the relationship between amyloid beta and memory recall. Neurobiology of Aging, 2018, 71, 142-148. | 1.5 | 31 |
| 88 | Quantitative PET and Histology of Brain Biopsy Reveal Lack of Selective Pittsburgh Compound-B Binding to Intracerebral Amyloidoma. Journal of Alzheimer's Disease, 2018, 65, 71-77. | 1.2 | 2 |
| 89 | Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale. Alzheimer's and Dementia, 2018, 14, 1565-1571. | 0.4 | 98 |
| 90 | Longitudinal changes in amyloid positron emission tomography and volumetric magnetic resonance imaging in the nondemented Down syndrome population. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 9, 1-9. | 1.2 | 49 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Pathological correlations of [¹⁸ F]AV ¹⁴⁵¹ imaging in non-Alzheimer tauopathies. <i>Annals of Neurology</i> , 2017, 81, 117-128. | 2.8 | 174 |
| 92 | Small-molecule PET Tracers for Imaging Proteinopathies. <i>Seminars in Nuclear Medicine</i> , 2017, 47, 553-575. | 2.5 | 91 |
| 93 | Cognitive decline and brain amyloid- β accumulation across 3 years in adults with Down syndrome. <i>Neurobiology of Aging</i> , 2017, 58, 68-76. | 1.5 | 59 |
| 94 | Association of Brain Amyloid- β With Slow Gait in Elderly Individuals Without Dementia. <i>JAMA Neurology</i> , 2017, 74, 82. | 4.5 | 66 |
| 95 | Alzheimer-Like Pattern of Hypometabolism Emerges with Elevated Amyloid- β Burden in Down Syndrome. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 631-644. | 1.2 | 23 |
| 96 | Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. <i>PLoS ONE</i> , 2016, 11, e0152082. | 1.1 | 45 |
| 97 | [¹⁸ F]AV ¹⁴⁵¹ positron emission tomography retention in choroid plexus: More than a "off-target" binding. <i>Annals of Neurology</i> , 2016, 80, 307-308. | 2.8 | 66 |
| 98 | Cerebral Amyloid Deposition and Dual-Tasking in Cognitively Normal, Mobility Unimpaired Older Adults. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2016, 72, glw211. | 1.7 | 12 |
| 99 | Tenascin-C Is Associated with Cored Amyloid- β Plaques in Alzheimer Disease and Pathology Burdened Cognitively Normal Elderly. <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 868-876. | 0.9 | 31 |
| 100 | Development of a Standardized Approach to Disclosing Amyloid Imaging Research Results in Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 17-24. | 1.2 | 35 |
| 101 | Post-mortem histopathology underlying β -amyloid PET imaging following flutemetamol F 18 injection. <i>Acta Neuropathologica Communications</i> , 2016, 4, 130. | 2.4 | 76 |
| 102 | The effects of normal aging on amyloid- β deposition in nondemented adults with Down syndrome as imaged by carbon 11-labeled Pittsburgh compound B. <i>Alzheimer's and Dementia</i> , 2016, 12, 380-390. | 0.4 | 65 |
| 103 | Comparison of qualitative and quantitative imaging characteristics of [¹¹ C]PiB and [¹⁸ F]flutemetamol in normal control and Alzheimer's subjects. <i>NeuroImage: Clinical</i> , 2015, 9, 592-598. | 1.4 | 48 |
| 104 | A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 50. | 3.0 | 10 |
| 105 | Validating novel tau positron emission tomography tracer [¹⁸ F]AV ¹⁴⁵¹ (T807) on postmortem brain tissue. <i>Annals of Neurology</i> , 2015, 78, 787-800. | 2.8 | 535 |
| 106 | Amyloid- β Imaging in Older Adults Presenting to a Memory Clinic with Subjective Cognitive Decline: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2015, 48, S151-S159. | 1.2 | 80 |
| 107 | More evidence for association of a rare TREM2 mutation (R47H) with Alzheimer's disease risk. <i>Neurobiology of Aging</i> , 2015, 36, 2443.e21-2443.e26. | 1.5 | 39 |
| 108 | The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET. <i>Alzheimer's and Dementia</i> , 2015, 11, 1. | 0.4 | 603 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Endogenous murine A β increases amyloid deposition in APP23 but not in APPS1 transgenic mice. <i>Neurobiology of Aging</i> , 2015, 36, 2241-2247. | 1.5 | 9 |
| 110 | Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study. <i>Lancet Neurology</i> , The, 2015, 14, 804-813. | 4.9 | 91 |
| 111 | Where is hippocampal activity in the cascade of Alzheimer's disease biomarkers?. <i>Brain</i> , 2015, 138, 831-833. | 3.7 | 8 |
| 112 | Incidental Cerebral Microbleeds and Cerebral Blood Flow in Elderly Individuals. <i>JAMA Neurology</i> , 2015, 72, 1021. | 4.5 | 71 |
| 113 | Subjective Cognitive Complaints, Personality and Brain Amyloid-beta in Cognitively Normal Older Adults. <i>American Journal of Geriatric Psychiatry</i> , 2015, 23, 985-993. | 0.6 | 112 |
| 114 | Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1924. | 3.8 | 1,166 |
| 115 | Prevalence of Amyloid PET Positivity in Dementia Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1939. | 3.8 | 501 |
| 116 | Relative ¹¹ C-PiB Delivery as a Proxy of Relative CBF: Quantitative Evaluation Using Single-Session ¹⁵ O-Water and ¹¹ C-PiB PET. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1199-1205. | 2.8 | 62 |
| 117 | Amyloid- β ¹¹ C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. <i>Neurology</i> , 2015, 85, 692-700. | 1.5 | 136 |
| 118 | Hyperphosphorylated Tau is Elevated in Alzheimer's Disease with Psychosis. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 759-773. | 1.2 | 46 |
| 119 | Amyloid Imaging With Carbon 11 ¹⁴ C-Labeled Pittsburgh Compound B for Traumatic Brain Injury. <i>JAMA Neurology</i> , 2014, 71, 23. | 4.5 | 132 |
| 120 | Arterial Stiffness and β -Amyloid Progression in Nondemented Elderly Adults. <i>JAMA Neurology</i> , 2014, 71, 562. | 4.5 | 152 |
| 121 | Early detection of Alzheimer's disease using PiB and FDG PET. <i>Neurobiology of Disease</i> , 2014, 72, 117-122. | 2.1 | 164 |
| 122 | Markers of cholesterol transport are associated with amyloid deposition in the brain. <i>Neurobiology of Aging</i> , 2014, 35, 802-807. | 1.5 | 62 |
| 123 | Amyloid, neurodegeneration, and small vessel disease as predictors of dementia in the oldest-old. <i>Neurology</i> , 2014, 83, 1804-1811. | 1.5 | 46 |
| 124 | Cognitive functioning in relation to brain amyloid- β in healthy adults with Down syndrome. <i>Brain</i> , 2014, 137, 2556-2563. | 3.7 | 87 |
| 125 | Amyloid burden and neural function in people at risk for Alzheimer's Disease. <i>Neurobiology of Aging</i> , 2014, 35, 576-584. | 1.5 | 166 |
| 126 | Development and Screening of Contrast Agents for In Vivo Imaging of Parkinson's Disease. <i>Molecular Imaging and Biology</i> , 2013, 15, 585-595. | 1.3 | 21 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 127 | Amyloid and neurodegeneration. <i>Neurology</i> , 2013, 81, 1728-1729. | 1.5 | 6 |
| 128 | Cognitive aging in persons with minimal amyloid- β^2 and white matter hyperintensities. <i>Neuropsychologia</i> , 2013, 51, 2202-2209. | 0.7 | 31 |
| 129 | Disclosure of amyloid imaging results to research participants: Has the time come?. <i>Alzheimer's and Dementia</i> , 2013, 9, 741. | 0.4 | 37 |
| 130 | Classification of amyloid-positivity in controls: Comparison of visual read and quantitative approaches. <i>NeuroImage</i> , 2013, 71, 207-215. | 2.1 | 77 |
| 131 | Imaging Tau Deposits In Vivo: Progress in Viewing More of The Proteopathy Picture. <i>Neuron</i> , 2013, 79, 1035-1037. | 3.8 | 13 |
| 132 | Cognitive trajectories associated with β^2 -amyloid deposition in the oldest-old without dementia. <i>Neurology</i> , 2013, 80, 1378-1384. | 1.5 | 77 |
| 133 | Pulse wave velocity is associated with β^2 -amyloid deposition in the brains of very elderly adults. <i>Neurology</i> , 2013, 81, 1711-1718. | 1.5 | 156 |
| 134 | Positron emission tomography radioligands for <i>in vivo</i> imaging of A β^2 plaques. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2013, 56, 89-95. | 0.5 | 53 |
| 135 | In vivo assessment of amyloid β^2 deposition in nondemented very elderly subjects. <i>Annals of Neurology</i> , 2013, 73, 751-761. | 2.8 | 89 |
| 136 | Anomalous PiB enhancement in the Superior Sagittal and Transverse Venous Sinuses. <i>Alzheimer Disease and Associated Disorders</i> , 2012, 26, 186-190. | 0.6 | 1 |
| 137 | Using Pittsburgh Compound B for In Vivo PET Imaging of Fibrillar Amyloid-Beta. <i>Advances in Pharmacology</i> , 2012, 64, 27-81. | 1.2 | 78 |
| 138 | Developing an international network for Alzheimer's research: the Dominantly Inherited Alzheimer Network. <i>Clinical Investigation</i> , 2012, 2, 975-984. | 0.0 | 180 |
| 139 | Brain Imaging in Alzheimer Disease. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a006213-a006213. | 2.9 | 502 |
| 140 | Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2012, 367, 795-804. | 13.9 | 3,005 |
| 141 | Correspondence between in vivo 11C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques. <i>Acta Neuropathologica</i> , 2012, 124, 823-831. | 3.9 | 98 |
| 142 | Amyloid imaging in dementias with atypical presentation. , 2012, 8, 389-398. | | 46 |
| 143 | Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B. <i>Alzheimer's and Dementia</i> , 2012, 8, 496-501. | 0.4 | 116 |
| 144 | β^2 -Amyloid 42/40 ratio and kalirin expression in Alzheimer disease with psychosis. <i>Neurobiology of Aging</i> , 2012, 33, 2807-2816. | 1.5 | 40 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Development of Positron Emission Tomography β -Amyloid Plaque Imaging Agents. <i>Seminars in Nuclear Medicine</i> , 2012, 42, 423-432. | 2.5 | 155 |
| 146 | Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab. <i>Archives of Neurology</i> , 2012, 69, 198. | 4.9 | 349 |
| 147 | Positron emission tomography imaging of amyloid-beta plaque deposition: a decade of translation. <i>Journal of Translational Medicine</i> , 2012, 10, . | 1.8 | 1 |
| 148 | β Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 209-219. | 3.3 | 55 |
| 149 | Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study. <i>Acta Neuropathologica</i> , 2012, 123, 433-447. | 3.9 | 78 |
| 150 | Inter-rater reliability of manual and automated region-of-interest delineation for PiB PET. <i>NeuroImage</i> , 2011, 55, 933-941. | 2.1 | 47 |
| 151 | Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. <i>Trends in Neurosciences</i> , 2011, 34, 430-442. | 4.2 | 309 |
| 152 | Lack of association between 11C-PiB and longitudinal brain atrophy in non-demented older individuals. <i>Neurobiology of Aging</i> , 2011, 32, 2123-2130. | 1.5 | 39 |
| 153 | Amyloid imaging as a biomarker for cerebral β -amyloidosis and risk prediction for Alzheimer dementia. <i>Neurobiology of Aging</i> , 2011, 32, S20-S36. | 1.5 | 120 |
| 154 | The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011, 7, 263-269. | 0.4 | 12,681 |
| 155 | Longitudinal assessment of β and cognition in aging and Alzheimer disease. <i>Annals of Neurology</i> , 2011, 69, 181-192. | 2.8 | 730 |
| 156 | In Vivo Fibrillar β -Amyloid Detected Using [11C]PiB Positron Emission Tomography and Neuropathologic Assessment in Older Adults. <i>Archives of Neurology</i> , 2011, 68, 232-40. | 4.9 | 102 |
| 157 | The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. , 2011, 7, 263. | | 1 |
| 158 | 11C-PiB PET assessment of change in fibrillar amyloid- β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. <i>Lancet Neurology</i> , The, 2010, 9, 363-372. | 4.9 | 674 |
| 159 | Progression of Cerebral Amyloid Load Is Associated with the Apolipoprotein E ϵ 4 Genotype in Alzheimer's Disease. <i>Biological Psychiatry</i> , 2010, 68, 879-884. | 0.7 | 103 |
| 160 | Consideration of Optimal Time Window for Pittsburgh Compound B PET Summed Uptake Measurements. <i>Journal of Nuclear Medicine</i> , 2009, 50, 348-355. | 2.8 | 108 |
| 161 | Basal Cerebral Metabolism May Modulate the Cognitive Effects of β in Mild Cognitive Impairment: An Example of Brain Reserve. <i>Journal of Neuroscience</i> , 2009, 29, 14770-14778. | 1.7 | 217 |
| 162 | Fibrillar amyloid- β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 6820-6825. | 3.3 | 700 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | Absence of Pittsburgh Compound B Detection of Cerebral Amyloid β^2 in a Patient With Clinical, Cognitive, and Cerebrospinal Fluid Markers of Alzheimer Disease. <i>Archives of Neurology</i> , 2009, 66, 1557-62. | 4.9 | 188 |
| 164 | Amyloid imaging in mild cognitive impairment subtypes. <i>Annals of Neurology</i> , 2009, 65, 557-568. | 2.8 | 309 |
| 165 | Update on amyloid imaging: From healthy aging to Alzheimer's disease. <i>Current Neurology and Neuroscience Reports</i> , 2009, 9, 345-352. | 2.0 | 55 |
| 166 | PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET. <i>Neurobiology of Aging</i> , 2009, 30, 1217-1226. | 1.5 | 118 |
| 167 | Clinical severity of Alzheimer's disease is associated with PIB uptake in PET. <i>Neurobiology of Aging</i> , 2009, 30, 1902-1909. | 1.5 | 89 |
| 168 | Beta Amyloid in Alzheimer's Disease: Increased Deposition in Brain Is Reflected in Reduced Concentration in Cerebrospinal Fluid. <i>Biological Psychiatry</i> , 2009, 65, 927-934. | 0.7 | 256 |
| 169 | Amyloid Imaging with PET in Alzheimer's Disease, Mild Cognitive Impairment, and Clinically Unimpaired Subjects. , 2009, , 119-147. | | 9 |
| 170 | 14 Amyloid Imaging and (What is "Normal"?) Aging. , 2009, , 191-244. | | 2 |
| 171 | Measuring Target Effect of Proposed Disease-Modifying Therapies in Alzheimer's Disease. <i>Neurotherapeutics</i> , 2008, 5, 381-390. | 2.1 | 23 |
| 172 | Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh Compound B. <i>Journal of Neuroscience Methods</i> , 2008, 172, 277-282. | 1.3 | 75 |
| 173 | Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. <i>NeuroImage</i> , 2008, 39, 619-633. | 2.1 | 201 |
| 174 | Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly. <i>Archives of Neurology</i> , 2008, 65, 1509. | 4.9 | 923 |
| 175 | Biopsy Support for the Validity of Pittsburgh Compound B Positron Emission Tomography With a Twist. <i>Archives of Neurology</i> , 2008, 65, 1281-3. | 4.9 | 11 |
| 176 | Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. <i>Brain</i> , 2008, 131, 1630-1645. | 3.7 | 837 |
| 177 | Longitudinal Cerebral Blood Flow and Amyloid Deposition: An Emerging Pattern?. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1465-1471. | 2.8 | 59 |
| 178 | ^{11}C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnesic mild cognitive impairment. <i>Brain</i> , 2008, 131, 665-680. | 3.7 | 819 |
| 179 | Imaging Alzheimer Pathology in Late-Life Depression With PET and Pittsburgh Compound-B. <i>Alzheimer Disease and Associated Disorders</i> , 2008, 22, 261-268. | 0.6 | 119 |
| 180 | Whatever Happened to Pittsburgh Compound-A?. <i>Alzheimer Disease and Associated Disorders</i> , 2008, 22, 198-203. | 0.6 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation. <i>Current Opinion in Neurology</i> , 2008, 21, 683-687. | 1.8 | 85 |
| 182 | Â-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. <i>Brain</i> , 2007, 130, 2837-2844. | 3.7 | 739 |
| 183 | Amyloid Deposition Begins in the Striatum of Presenilin-1 Mutation Carriers from Two Unrelated Pedigrees. <i>Journal of Neuroscience</i> , 2007, 27, 6174-6184. | 1.7 | 358 |
| 184 | Molecular Imaging With Pittsburgh Compound B Confirmed at Autopsy. <i>Archives of Neurology</i> , 2007, 64, 431. | 4.9 | 326 |
| 185 | Impact of amyloid imaging on drug development in Alzheimer's disease. <i>Nuclear Medicine and Biology</i> , 2007, 34, 809-822. | 0.3 | 115 |
| 186 | Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease. <i>NeuroImage</i> , 2007, 36, 298-312. | 2.1 | 96 |
| 187 | Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. <i>Annals of Neurology</i> , 2007, 62, 229-234. | 2.8 | 465 |
| 188 | Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease. <i>NeuroImage</i> , 2006, 33, 94-102. | 2.1 | 116 |
| 189 | Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid A β 242 in humans. <i>Annals of Neurology</i> , 2006, 59, 512-519. | 2.8 | 1,190 |
| 190 | Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. <i>Brain</i> , 2006, 129, 2805-2807. | 3.7 | 54 |
| 191 | X α 34 Labeling of Abnormal Protein Aggregates During the Progression of Alzheimer's Disease. <i>Methods in Enzymology</i> , 2006, 412, 123-144. | 0.4 | 52 |
| 192 | Kinetic Modeling of Amyloid Binding in Humans using PET Imaging and Pittsburgh Compound-B. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, 1528-1547. | 2.4 | 622 |
| 193 | In Vivo Optical Imaging of Amyloid Aggregates in Brain: Design of Fluorescent Markers. <i>Angewandte Chemie - International Edition</i> , 2005, 44, 5452-5456. | 7.2 | 303 |
| 194 | Imaging Technology for Neurodegenerative Diseases. <i>Archives of Neurology</i> , 2005, 62, 196. | 4.9 | 69 |
| 195 | Role of biomarkers in studies of presymptomatic Alzheimer's disease. , 2005, 1, 145-151. | | 23 |
| 196 | Commentary on "Diagnosis of Alzheimer's disease: Two decades of progress." • Diagnosis of Alzheimer's disease: Walking a well-paved path. , 2005, 1, 99-100. | | 0 |
| 197 | Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory. <i>Journal of Neuroscience</i> , 2005, 25, 7709-7717. | 1.7 | 1,839 |
| 198 | Binding of the Positron Emission Tomography Tracer Pittsburgh Compound-B Reflects the Amount of Amyloid-Â in Alzheimer's Disease Brain But Not in Transgenic Mouse Brain. <i>Journal of Neuroscience</i> , 2005, 25, 10598-10606. | 1.7 | 357 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 199 | Simplified quantification of PIB amyloid imaging PET studies. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S589-S589. | 2.4 | 3 |
| 200 | Anti-A β 2 antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. <i>Journal of Clinical Investigation</i> , 2005, 115, 428-433. | 3.9 | 161 |
| 201 | Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. <i>Journal of Nuclear Medicine</i> , 2005, 46, 1959-72. | 2.8 | 398 |
| 202 | Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. <i>Annals of Neurology</i> , 2004, 55, 306-319. | 2.8 | 3,777 |
| 203 | Targeting Prion Amyloid Deposits In Vivo. <i>Journal of Neuropathology and Experimental Neurology</i> , 2004, 63, 775-784. | 0.9 | 32 |
| 204 | Synthesis and Evaluation of ¹¹ C-Labeled 6-Substituted 2-Arylbenzothiazoles as Amyloid Imaging Agents. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 2740-2754. | 2.9 | 921 |
| 205 | Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography. <i>Neuroimaging Clinics of North America</i> , 2003, 13, 781-789. | 0.5 | 74 |
| 206 | Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid- β ligand in transgenic mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 12462-12467. | 3.3 | 253 |
| 207 | The Binding of 2-(4-Methylaminophenyl)Benzothiazole to Postmortem Brain Homogenates Is Dominated by the Amyloid Component. <i>Journal of Neuroscience</i> , 2003, 23, 2086-2092. | 1.7 | 269 |
| 208 | Imaging A β 2 Plaques in Living Transgenic Mice with Multiphoton Microscopy and Methoxy-X04, a Systemically Administered Congo Red Derivative. <i>Journal of Neuropathology and Experimental Neurology</i> , 2002, 61, 797-805. | 0.9 | 366 |
| 209 | Apolipoprotein E and Alpha-1-Antichymotrypsin Genotypes Do Not Predict Time to Psychosis in Alzheimer's Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2002, 15, 24-30. | 1.2 | 20 |
| 210 | Blood and CSF biomarkers for AD revisited: what's new, what's good, and is this where we should be looking?. <i>Neurobiology of Aging</i> , 2002, 23, 517-519. | 1.5 | 9 |
| 211 | Psychosis in Alzheimer disease: postmortem magnetic resonance spectroscopy evidence of excess neuronal and membrane phospholipid pathology. <i>Neurobiology of Aging</i> , 2002, 23, 547-553. | 1.5 | 60 |
| 212 | Synthesis and ¹¹ C-labelling of (E,E)-1-(3,4-dihydroxystyryl)-4-(3-methoxy-4-hydroxystyryl) benzene for PET imaging of amyloid deposits?. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2002, 45, 647-664. | 0.5 | 22 |
| 213 | A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2002, 12, 295-298. | 1.0 | 343 |
| 214 | Visualization of fibrillar amyloid deposits in living, transgenic <i>Caenorhabditis elegans</i> animals using the sensitive amyloid dye, X-34. <i>Neurobiology of Aging</i> , 2001, 22, 217-226. | 1.5 | 147 |
| 215 | Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. <i>Life Sciences</i> , 2001, 69, 1471-1484. | 2.0 | 408 |
| 216 | The 5-HTTPR Polymorphism Confers Liability to a Combined Phenotype of Psychotic and Aggressive Behavior in Alzheimer Disease. <i>International Psychogeriatrics</i> , 2001, 13, 401-409. | 0.6 | 103 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 217 | Psychotic Symptoms in Alzheimer's Disease Are Not Associated With More Severe Neuropathologic Features. <i>International Psychogeriatrics</i> , 2000, 12, 547-558. | 0.6 | 56 |
| 218 | X-34, A Fluorescent Derivative of Congo Red: A Novel Histochemical Stain for Alzheimer's Disease Pathology. <i>Journal of Histochemistry and Cytochemistry</i> , 2000, 48, 1223-1232. | 1.3 | 253 |
| 219 | Quantifying Amyloid β -Peptide ($A\beta$) Aggregation Using the Congo Red- $A\beta$ (CR- $A\beta$) Spectrophotometric Assay. <i>Analytical Biochemistry</i> , 1999, 266, 66-76. | 1.1 | 283 |
| 220 | Effect of phosphomonoesters, phosphodiesterases, and phosphocreatine on glutamate uptake by synaptic vesicles. <i>Molecular and Chemical Neuropathology</i> , 1997, 32, 89-99. | 1.0 | 5 |
| 221 | Aggregation of β -Amyloid Peptide Is Promoted by Membrane Phospholipid Metabolites Elevated in Alzheimer's Disease Brain. <i>Journal of Neurochemistry</i> , 1997, 69, 266-272. | 2.1 | 25 |
| 222 | Magnetic Resonance Spectroscopy of Neural Tissue. <i>Methods in Neurosciences</i> , 1996, , 178-208. | 0.5 | 1 |
| 223 | Structural determinants of activity at the GABAB receptor. <i>Molecular and Chemical Neuropathology</i> , 1995, 26, 15-30. | 1.0 | 9 |
| 224 | Development of small molecule probes for the Beta-amyloid protein of Alzheimer's Disease. <i>Neurobiology of Aging</i> , 1994, 15, 691-698. | 1.5 | 171 |
| 225 | Alterations of cerebral metabolism in probable Alzheimer's disease: A preliminary study. <i>Neurobiology of Aging</i> , 1994, 15, 117-132. | 1.5 | 171 |
| 226 | Analysis of magnetic resonance spectra by mole percent: Comparison to absolute units. <i>Neurobiology of Aging</i> , 1994, 15, 133-140. | 1.5 | 76 |
| 227 | NMR Identification of the Formic Acid-Modified Residue in Alzheimer's Amyloid Protein. <i>Journal of Neurochemistry</i> , 1994, 62, 349-354. | 2.1 | 15 |
| 228 | L-Phosphoserine, a Metabolite Elevated in Alzheimer's Disease, Interacts with Specific L-Glutamate Receptor Subtypes. <i>Journal of Neurochemistry</i> , 1991, 56, 1997-2003. | 2.1 | 30 |
| 229 | Alzheimer's β -Amyloid Protein Is Covalently Modified when Dissolved in Formic Acid. <i>Journal of Neurochemistry</i> , 1990, 54, 2050-2056. | 2.1 | 26 |
| 230 | CSF Biomarkers in Down Syndrome and Autosomal Dominant Alzheimer Disease. <i>SSRN Electronic Journal</i> , 0, , . | 0.4 | 0 |